Signal Genetics, Inc., a commercial stage molecular genetic diagnostic company, focuses on providing diagnostic services that assist physicians in decision making for the care of patients suffering from cancer. It offers Myeloma Prognostic Risk Signature (MyPRS) test, a microarray-based gene expression profile assay to test the presence of various groups of genes that predict low or high level risk of early relapse in patients suffering from multiple myeloma. The company holds license to the intellectual property developed at Myeloma Institute for Research and Therapy in University of Arkansas for Medical Sciences. Signal Genetics, Inc. was founded in 2010 and is headquartered in Carlsbad, California.
FreeSeas Inc., through its subsidiaries, provides drybulk shipping services. Its vessels carry various drybulk commodities, such as iron ore, grain, and coal, as well as bauxite, phosphate, fertilizers, steel products, cement, sugar, and rice. Its fleet consists of five Handysize vessels and one Handymax vessel. As of April 23, 2015, its operational fleet had approximately 148,978 deadweight tons with the average age of 17.7 years. The company was formerly known as Adventure Holdings S.A. and changed its name to FreeSeas Inc. in April 2005. FreeSeas Inc. was founded in 2004 and is based in Athens, Greece.
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the screening for precancerous polyps and colorectal cancer. Its lead product is an endoscopy capsule with a colon imaging system for colorectal cancer and pre-cancerous polyps that utilizes X-ray-based measurement technology to generate 3-dimensional imagery of the colon without cleansing or other aggressive bowel preparation. The company was founded in 2004 and is headquartered in Mount Carmel, Israel.
RCS Capital Corporation engages in the independent retail advice, wholesale distribution, investment banking, capital markets, investment management, and investment research businesses. The company offers independent retail advices, financial products, and investment solutions through a network of independent channel broker-dealers and registered investment advisers; and multi-product distribution platform of direct investment program offerings to independent broker-dealers and the retail financial advisor community. It also operates as a registrar; provides record-keeping services; and executes the transfer, issuance, and cancellation of shares or other securities in connection with offerings conducted by issuers. In addition, the company provides strategic advisory services comprising advising sponsors in the structuring and development of new direct investment programs, and registered investment funds and other products; advising sponsors and companies with respect to direct investment programs; advising direct investment programs primarily for non-traded real estate investment trusts in connection with liquidity alternatives, which include listing on a national securities exchange and initial public offering transactions; and debt and equity capital raising advisory services, such as structuring, pricing, and marketing services. Further, it offers transaction management services, such as services related to offering registration and blue sky filings; regulatory advice; registration maintenance; transaction management; marketing support; due diligence advice and related meetings; events; training and education; conference management; and strategic advice. The company was formerly known as 405 Holding Corporation and changed its name to RCS Capital Corporation in February 2013. RCS Capital Corporation was incorporated in 2012 and is headquartered in New York, New York.
Asterias Biotherapeutics, Inc., a biotechnology company, focuses on the emerging field of regenerative medicines. It is developing pluripotent stem-cell therapeutic products in the areas of neurology and oncology. The company's product candidates include AST-OPC1, which is in Phase I/IIa clinical trial for the treatment of spinal cord injury, multiple sclerosis, and stroke; and AST-VAC2, the allogeneic dendritic cells loaded with telomerase antigen for the treatment of non-small cell lung cancer, as well as multiple cancer types, antigens, and infectious diseases. It is also developing AST-VAC1 for the treatment of prostate cancer and acute myelogenous leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is based in Menlo Park, California. Asterias Biotherapeutics, Inc. is a subsidiary of BioTime, Inc.
Majesco Entertainment Company develops, publishes, and distributes video game products primarily for casual-game consumers worldwide. The company publishes video games for various interactive entertainment hardware platforms, including Nintendo's DS, DSi, 3DS, Wii and WiiU, Sony's PlayStation 3, Microsoft's Xbox 360 and Xbox One, and the personal computers. It also publishes games for various digital platforms consisting of Xbox Live Arcade and PlayStation Network; mobile platforms, such as the iOS and Android phones; and online platforms, including Facebook and Steam. The company sells its products primarily to large retail chains, specialty retail stores, video game rental outlets, and distributors. Majesco Entertainment Company was founded in 1998 and is based in Edison, New Jersey.
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, tregs, and myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. Its lead product ADXS-HPV, an Lm-LLO immunotherapy product candidate used for the treatment of human papilloma virus (HPV) associated cancers, completed its Phase II study. The company is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate designed to target the PSA antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate for the treatment of Her2 expressing cancers, including human and canine osteosarcoma, breast, gastric, and other cancers. It has a clinical trial collaboration with MedImmune, LLC to evaluate MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor in combination with ADXS-HPV, a cancer immunotherapy vaccine to treat patients with cervical cancer, and HPV-associated head and neck cancer. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies for cancer patients. Its proprietary product platform creates small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases (HMTs). The company has two HMTs inhibitors in clinical development for the treatment of patients with cancers. It is conducting a Phase I/II clinical trial of EPZ-6438, an inhibitor that targets the EZH2 HMT for the treatment of non-Hodgkin lymphoma and advanced solid tumors, including INI1-deficient tumors, such as synovial sarcoma and malignant rhabdoid tumors; and two Phase 1 clinical trials of EPZ-5676, an inhibitor targeting the DOT1L HMT for the treatment of acute leukemia with genetic alterations of the MLL gene. It has therapeutic collaborations with Celgene Corporation and Celgene International Srl; Eisai Co., Ltd.; and Glaxo Group Limited., as well as companion diagnostic development collaborations with Roche Molecular Systems, Inc. and Abbott Molecular Inc. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Amyris, Inc. provides various alternatives to a range of petroleum-sourced products for the consumer care, specialty chemical, and transportation fuel markets worldwide. The company applies its industrial synthetic biology platform to design microbes and primarily yeast, as well as to convert plant-sourced sugars into renewable hydrocarbons. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market. The company also provides renewable solvents, polymers, and various materials for performance materials market; renewable fuels for transportation fuels market; and base oils for lubricants market. It has a collaboration partnership with Total to commercialize Biofene-based diesel and jet fuels. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.
Code Rebel Corporation develops, markets, and licenses its interactive remote application terminal services solution (iRAPP). Its iRAPP allows personal computers (PCs) users to use applications on a single Mac remote desktop simultaneously via the iRAPP client or any standard compliant remote desktop protocol client. The company offers iRAPP client-side products, which allow an end user to connect from a PC to a Mac remote desktop within the Windows environment; terminal services products that enable a large number of end users to remotely access Mac computer applications and data stored on a central management server from various computer and mobile electronic devices; and access products, which provide additional connectivity and functionality to its terminal services products. Code Rebel Corporation was founded in 2007 and is based in Kahului, Hawaii.